

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number
WO 02/26718 A2

(51) International Patent Classification⁷: C07D 239/91,
401/04, 409/14, 401/14, 487/04, A61K 31/517, 31/519,
A61P 7/02

Moon Bay, CA 94019 (US). ZHU, Bing-Yan [CA/US];
135 Lois Lane, Palo Alto, CA 94303 (US).

(21) International Application Number: PCT/US01/30335

(74) Agent: LEE, Christine, S.; Morgan, Lewis & Bockius
LLP, 1800 M Street, N.W., Washington, DC 20036-5869
(US).

(22) International Filing Date: 1 October 2001 (01.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/236,331 29 September 2000 (29.09.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(71) Applicant (*for all designated States except US*): COR
THERAPEUTICS, INC. [US/US]; 256 East Grand
Avenue, South San Francisco, CA 94080 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): ZHANG, Penglie
[CN/US]; 251 Winchester Court, Foster City, CA 94404
(US). LI, Wenhao [CN/US]; P.O. Box 1993, South San
Francisco, CA 94083 (US). HUANG, Wenrong [CN/US];
7723 Huntridge Lane, Cupertino, CA 95014 (US). WANG,
Lingyan [CN/US]; 25 Hickory Place # H-21, Chatham,
NJ 07928 (US). JIA, Zhaozhong, Jon [CN/US]; 1576-E
Marina Court, San Mateo, CA 94404 (US). SCARBOR-
OUGH, Robert, M. [US/US]; 22 Greenbrier Court, Half

Published:

— without international search report and to be republished
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: BICYCLIC PYRIMIDIN-4-ONE BASED INHIBITORS OF FACTOR XA



(57) Abstract: Novel bicyclic pyrimidin-4-one-containing compounds of formulae (I) or (II): including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful *in vitro* or *in vivo* for preventing or treating conditions in mammals characterized by undesired thrombosis.

WO 02/26718 A2

BICYCLIC PYRIMIDIN-4-ONE BASED INHIBITORS OF FACTOR Xa

Field of the Invention

The invention relates to novel bicyclic pyrimidin-4-one-containing
5 compounds including their pharmaceutically acceptable isomers, salts, hydrates,
solvates and prodrug derivatives, and pharmaceutically acceptable compositions
thereof which are potent and highly selective inhibitors of isolated factor Xa or when
assembled in the prothrombinase complex. These compounds show selectivity for
factor Xa versus other proteases of the coagulation (e.g. thrombin, fVIIa, fIXa) or
10 the fibrinolytic cascades (e.g. plasminogen activators, plasmin). In another aspect,
the present invention relates to novel bicyclic pyrimidin-4-one-containing
compounds including their pharmaceutically acceptable isomers, salts, hydrates,
solvates and prodrug derivatives factor Xa-inhibiting compounds, and
pharmaceutically acceptable compositions thereof which are useful as potent and
15 specific inhibitors of blood coagulation in mammals. In yet another aspect, the
invention relates to methods for using these inhibitors as therapeutic agents for
disease states in mammals characterized by undesired thrombosis or coagulation
disorders.

20 Background of the Invention

Hemostasis, the control of bleeding, occurs by surgical means, or by the
physiological properties of vasoconstriction and coagulation. This invention is
particularly concerned with blood coagulation and ways in which it assists in
maintaining the integrity of mammalian circulation after injury, inflammation,
25 disease, congenital defect, dysfunction or other disruption. Although platelets and
blood coagulation are both involved in thrombus formation, certain components of
the coagulation cascade are primarily responsible for the amplification or
acceleration of the processes involved in platelet aggregation and fibrin deposition.

Thrombin is a key enzyme in the coagulation cascade as well as in
30 hemostasis. Thrombin plays a central role in thrombosis through its ability to
catalyze the conversion of fibrinogen into fibrin and through its potent platelet

activation activity. Direct or indirect inhibition of thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson, G., "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", *Blood Coag. Fibrinol.* 5, 411-436 (1994). Several classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e. heparins, low-molecular weight heparins, heparin-like compounds and coumarins).

A prothrombinase complex, including Factor Xa (a serine protease, the activated form of its Factor X precursor and a member of the calcium ion binding, gamma carboxyglutamyl (Gla)-containing, vitamin K dependent, blood coagulation glycoprotein family), converts the zymogen prothrombin into the active procoagulant thrombin. Unlike thrombin, which acts on a variety of protein substrates as well as at a specific receptor, factor Xa appears to have a single physiologic substrate, namely prothrombin. Since one molecule of factor Xa may be able to generate up to 138 molecules of thrombin (Elodi et al., *Thromb. Res.* 15, 617-619 (1979)), direct inhibition of factor Xa as a way of indirectly inhibiting the formation of thrombin may be an efficient anticoagulant strategy. Therefore, it has been suggested that compounds which selectively inhibit factor Xa may be useful as *in vitro* diagnostic agents, or for therapeutic administration in certain thrombotic disorders, see e.g., WO 94/13693.

Polypeptides derived from hematophagous organisms have been reported which are highly potent and specific inhibitors of factor Xa. United States Patent 4,588,587 describes anticoagulant activity in the saliva of the Mexican leech, *Haementeria officinalis*. A principal component of this saliva was shown to be the polypeptide factor Xa inhibitor, antistasin (ATS), by Nutt, E. *et al.*, "The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure", *J. Biol. Chem.*, 263, 10162-10167 (1988). Another potent and highly specific inhibitor of Factor Xa, called tick anticoagulant peptide (TAP), has been isolated from the whole body extract of the soft tick *Ornithodoros moubata*, as reported by Waxman, L., *et al.*, "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa" *Science*, 248, 593-596 (1990).

Factor Xa inhibitory compounds which are not large polypeptide-type inhibitors have also been reported including: Tidwell, R.R. *et al.*, "Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors", *Thromb. Res.*, 19, 339-349 (1980); Turner, A.D. *et al.*, "p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin", *Biochemistry*, 25, 4929-4935 (1986); Hitomi, Y. *et al.*, "Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System", *Haemostasis*, 15, 164-168 (1985); Sturzebecher, J. *et al.*, "Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency", *Thromb. Res.*, 54, 245-252 (1989); Kam, C.M. *et al.*, "Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants", *Biochemistry*, 27, 2547-2557 (1988); Hauptmann, J. *et al.*, "Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors", *Thromb. Haemost.*, 63, 220-223 (1990); and the like.

Others have reported Factor Xa inhibitors which are small molecule organic compounds, such as nitrogen containing heterocyclic compounds which have amidino substituent groups, wherein two functional groups of the compounds can bind to Factor Xa at two of its active sites. For example, WO 98/28269 describes pyrazole compounds having a terminal C(=NH)-NH₂ group; WO 97/21437 describes benzimidazole compounds substituted by a basic radical which are connected to a naphthyl group via a straight or branched chain alkylene, -C(=O) or -S(=O)₂ bridging group; WO 99/10316 describes compounds having a 4-phenyl-N-alkylamidino-piperidine and 4-phenoxy-N-alkylamidino-piperidine group connected to a 3-amidinophenyl group via a carboxamidealkyleneamino bridge; and EP 798295 describes compounds having a 4-phenoxy-N-alkylamidino-piperidine group connected to an amidinonaphthyl group via a substituted or unsubstituted sulfonamide or carboxamide bridging group.

There exists a need for effective therapeutic agents for the regulation of hemostasis, and for the prevention and treatment of thrombus formation and other pathological processes in the vasculature induced by thrombin such as restenosis and inflammation. In particular, there continues to be a need for compounds which



selectively inhibit factor Xa or its precursors. Compounds are needed which selectively or preferentially bind to Factor Xa. Compounds with a higher affinity for binding to Factor Xa than to thrombin are desired, especially those compounds having good bioavailability or other pharmacologically desirable properties.

5

Summary of the Invention


The present invention relates to novel bicyclic pyrimidin-4-one-containing compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvate and prodrug derivatives, which have particular biological properties and are
10 useful as potent and specific inhibitors of blood coagulation in mammals. According to the invention, the compounds can act as potent and highly selective inhibitors of isolated Factor Xa or when assembled in the prothrombinase complex. The invention also provides compositions containing such compounds. The compounds of the invention may be used as diagnostic reagents or as therapeutic
15 reagents for disease states in mammals which have coagulation disorders. Thus, the invention further provides methods for preventing or treating a condition in a mammal characterized by undesired thrombosis by administration of a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Optionally, the methods of the invention
20 comprise administering a pharmaceutical composition of the invention in combination with an additional therapeutic agent such as an antithrombotic and/or a thrombolytic agent and/or an anticoagulant. According to the invention, such conditions include, for example, any thrombotically mediated acute coronary or cerebrovascular syndrome, any thrombotic syndrome occurring in the venous
25 system, any coagulopathy, and any thrombotic complications associated with extracorporeal circulation or instrumentation, and for the inhibition of coagulation in biological samples (e.g. stored blood products and samples).

The invention provides a compound of the general formulae (I) or (II):



wherein:

A is a member selected from the group consisting of:



R^{1a} , R^{1b} , R^{1d} , and R^{1e} are each independently a H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, aryl, $-C_{1-6}$ alkylaryl, $-(CH_2)_{1-6}NR_aC(=O)C_{1-6}$ alkyl, $-(CH_2)_{1-6}C(=O)OH$, $-(CH_2)_{1-6}C(=O)OC_{1-6}$ alkyl, or $-(CH_2)_{1-6}C(=O)NR_aR_b$; or R^{1a} and R^{1b} or R^{1a} and R^{1c} or R^{1a} and R^{1d} or R^{1d} and R^{1e} taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8

membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein R^{1a} , R^{1b} , R^{1d} , or R^{1e} is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidiny, piperaziny, pyrrolidiny, aryl, morpholiny, and thiomorpholinyldioxide;


R^{1c} is H, C_{1-6} alkyl or C_{3-8} cycloalkyl;

- 10 R^{2a} , R^{2b} and R^{2c} are each independently a H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl, $-C_{3-8}$ cycloalkyl, aryl, $-C_{1-6}$ alkylaryl, $-(CH_2)_{1-6}NR_aC(=O)C_{1-6}$ alkyl, $-(CH_2)_{1-6}C(=O)OH$, $-(CH_2)_{1-6}C(=O)OC_{1-6}$ alkyl, or $-(CH_2)_{1-6}C(=O)NR_aR_b$; or R^{2a} and R^{2b} or R^{1a} , as set forth above, and R^{2a} or R^{1a} , as set forth above, and R^{2b} taken together with the nitrogen atom to which they are each attached can form a
- 15 substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein R^{2a} , R^{2b} or R^{2c} is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidiny, piperaziny, pyrrolidiny, aryl, morpholiny, and thiomorpholinyldioxide;
- 20

R_a and R_b are independently H, $-C_{1-6}$ alkyl, $-C_{2-6}$ alkenyl, $-C_{2-6}$ alkynyl; or R_a and R_b taken together with the nitrogen to which they are attached form azetidiny, pyrrolidiny, piperidiny, morpholiny, thiomorpholiny and its oxidized forms, piperaziny, 4-methyl-1-piperaziny, morpholinyaldehyde,

25 piperazinyaldehyde or thiomorpholinyaldehyde and its oxidized forms;

Q is a member selected from the group consisting of:



R^1 is a H, Cl, F, Br, I, $-C_{1-6}$ alkyl, $-OC_{1-6}$ alkyl, $-OhaloC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, $-NR_aR_b$, or $-SC_{1-6}$ alkyl, where R_a and R_b are as set forth above;

5 R^2 is a H, Cl, F, I, Br, $-OC_{1-6}$ alkyl or $-NR_aR_b$, where R_a and R_b are as set forth above;

R^3 , R^4 , R^5 , R^6 and R^7 are each H, -F, -Cl or -Br, OC_{1-6} alkyl, $-OhaloC_{1-6}$ alkyl, $-NR_aR_b$;

Y is CH or N;

10

X is O or S;

and

15 R is, in each occurrence, independently, H, -Cl, -Br, -I, -F, $-C_{1-6}$ alkyl, $-C_3$ -
 δ cycloalkyl, $-C_{0-6}$ alkyl- OC_{1-6} alkyl, $-C_{0-6}$ alkyl- $O(CH_2)_{1-4}$ -COOH,
 $-C_{0-6}$ alkyl- $O(CH_2)_{1-4}$ -C(=O) OC_{1-6} alkyl, $-C_{0-6}$ alkylCOOH, $-C_{0-6}$ alkylCO $_2C_{1-6}$ alkyl,
 $-C_{0-6}$ alkyl OC_{1-6} alkyl, $-C_{1-6}$ alkylOH, $-C_{0-6}$ alkylCONH $_2$, $-C_{0-6}$ alkylNH $_2$,
 $-C_{0-6}$ alkylNH(C_{1-6} alkyl) or $-C_{0-6}$ alkylN(C_{1-6} alkyl) $_2$,
 20 and all pharmaceutically acceptable isomers, salts, hydrates, solvates and
 prodrug derivatives thereof.

Detailed Description of the Invention

Definitions

25 In accordance with the present invention and as used herein, the following
 terms are defined with the following meanings, unless explicitly stated otherwise.

The term "alkenyl" refers to a trivalent straight chain or branched chain
 unsaturated aliphatic radical. The term "alkynyl" (or "alkynyl") refers to a straight or
 branched chain aliphatic radical that includes at least two carbons joined by a triple
 30 bond. If no number of carbons is specified alkenyl and alkynyl each refer to radicals
 having from 2-12 carbon atoms.

The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain and cyclic groups having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms. The term "cycloalkyl" as used herein refers to a mono-, bi-, or tricyclic aliphatic ring having 3 to 14 carbon atoms and preferably 3 to 7 carbon atoms.

As used herein, the terms "carbocyclic ring structure" and "C₃₋₁₆ carbocyclic mono, bicyclic or tricyclic ring structure" or the like are each intended to mean stable ring structures having only carbon atoms as ring atoms wherein the ring structure is a substituted or unsubstituted member selected from the group consisting of:

- a stable monocyclic ring which is aromatic ring ("aryl") having six ring atoms;
- a stable monocyclic non-aromatic ring having from 3 to 7 ring atoms in the ring;
- a stable bicyclic ring structure having a total of from 7 to 12 ring atoms in the two rings wherein the bicyclic ring structure is selected from the group consisting of ring structures in which both of the rings are aromatic, ring structures in which one of the rings is aromatic and ring structures in which both of the rings are non-aromatic; and
- a stable tricyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein the tricyclic ring structure is selected from the group consisting of: ring structures in which three of the rings are aromatic, ring structures in which two of the rings are aromatic and ring structures in which three of the rings are non-aromatic.

In each case, the non-aromatic rings when present in the monocyclic, bicyclic or tricyclic ring structure may independently be saturated, partially saturated or fully saturated. Examples of such carbocyclic ring structures include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin). Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any carbon atom which results in a stable structure. The term "substituted" as used in conjunction with carbocyclic ring structures means that hydrogen atoms attached to the ring carbon atoms of ring structures described herein may be substituted by one or more of the substituents indicated for that structure if such substitution(s) would result in a stable compound.

The term "aryl" which is included with the term "carbocyclic ring structure" refers to an unsubstituted or substituted aromatic ring, substituted with one, two or three substituents selected from loweralkoxy, loweralkyl, loweralkylamino, hydroxy, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, 5 carboalkoxy and carboxamide, including but not limited to carbocyclic aryl, heterocyclic aryl, and biaryl groups and the like, all of which may be optionally substituted. Preferred aryl groups include phenyl, halophenyl, loweralkylphenyl, naphthyl, biphenyl, phenanthrenyl and naphthacenyl.

The term "arylalkyl" which is included with the term "carbocyclic aryl" 10 refers to one, two, or three aryl groups having the number of carbon atoms designated, appended to an alkyl group having the number of carbon atoms designated. Suitable arylalkyl groups include, but are not limited to, benzyl, picolyl, naphthylmethyl, phenethyl, benzyhydril, trityl, and the like, all of which may be optionally substituted.

15 As used herein, the term "heterocyclic ring" or "heterocyclic ring system" is intended to mean a substituted or unsubstituted member selected from the group consisting of stable monocyclic ring having from 5-7 members in the ring itself and having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S; a stable bicyclic ring structure having a total of from 7 to 12 atoms in the two 20 rings wherein at least one of the two rings has from 1 to 4 hetero atoms selected from N, O and S, including bicyclic ring structures wherein any of the described stable monocyclic heterocyclic rings is fused to a hexane or benzene ring; and a stable tricyclic heterocyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein at least one of the three rings has from 1 to 4 hetero atoms 25 selected from the group consisting of N, O and S. Any nitrogen and sulfur atoms present in a heterocyclic ring of such a heterocyclic ring structure may be oxidized. Unless indicated otherwise the terms "heterocyclic ring" or "heterocyclic ring system" include aromatic rings, as well as non-aromatic rings which can be saturated, partially saturated or fully saturated non-aromatic rings. Also, unless 30 indicated otherwise the term "heterocyclic ring system" includes ring structures wherein all of the rings contain at least one hetero atom as well as structures having

less than all of the rings in the ring structure containing at least one hetero atom, for example bicyclic ring structures wherein one ring is a benzene ring and one of the rings has one or more hetero atoms are included within the term "heterocyclic ring systems" as well as bicyclic ring structures wherein each of the two rings has at least one hetero atom. Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any hetero atom or carbon atom which results in a stable structure. Further, the term "substituted" means that one or more of the hydrogen atoms on the ring carbon atom(s) or nitrogen atom(s) of the each of the rings in the ring structures described herein may be replaced by one or more of the indicated substituents if such replacement(s) would result in a stable compound. Nitrogen atoms in a ring structure may be quaternized, but such compounds are specifically indicated or are included within the term "a pharmaceutically acceptable salt" for a particular compound. When the total number of O and S atoms in a single heterocyclic ring is greater than 1, it is preferred that such atoms not be adjacent to one another. Preferably, there are no more than 1 O or S ring atoms in the same ring of a given heterocyclic ring structure.

Examples of monocyclic and bicyclic heterocyclic ring systems, in alphabetical order, are acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolyl, 1H-indazolyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenaziny, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl,

pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidiny, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiaziny, 1,2,3-thiadiazoly, 1,2,4-thiadiazoly, 1,2,5-thiadiazoly, 1,3,4-thiadiazoly, 5 thianthrenyl, thiazoly, thienyl, thienothiazoly, thienooxazoly, thienoimidazoly, thiophenyl, triaziny, 1,2,3-triazoly, 1,2,4-triazoly, 1,2,5-triazoly, 1,3,4-triazoly and xanthenyl. Preferred heterocyclic ring structures include, but are not limited to, pyridiny, furanyl, thienyl, pyrroly, pyrazoly, pyrrolidinyl, imidazoly, indoly, benzimidazoly, 1H-indazoly, oxazolinyl, or isatinoyl. Also included are fused ring 10 and spiro compounds containing, for example, the above heterocyclic ring structures.

As used herein the term "aromatic heterocyclic ring system" has essentially the same definition as for the monocyclic and bicyclic ring systems except that at least one ring of the ring system is an aromatic heterocyclic ring or the bicyclic ring has an aromatic or non-aromatic heterocyclic ring fused to an aromatic carbocyclic 15 ring structure.

The terms "halo" or "halogen" as used herein refer to Cl, Br, F or I substituents. The term "haloalkyl", and the like, refer to an aliphatic carbon radicals having at least one hydrogen atom replaced by a Cl, Br, F or I atom, including mixtures of different halo atoms. Trihaloalkyl includes trifluoromethyl and the like 20 as preferred radicals, for example.

The term "methylene" refers to $-CH_2-$.

The term "pharmaceutically acceptable salts" includes salts of compounds derived from the combination of a compound and an organic or inorganic acid. These compounds are useful in both free base and salt form. In practice, the use of 25 the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.

"Pharmaceutically acceptable acid addition salt" refers to salts retaining the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as 30 hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic

acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

"Pharmaceutically acceptable base addition salts" include those derived from
5 inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally
10 occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine,
15 piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.

"Biological property" for the purposes herein means an *in vivo* effector or antigenic function or activity that is directly or indirectly performed by a compound
20 of this invention that are often shown by *in vitro* assays. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or
25 antigenic site that is capable of reacting with antibodies raised against it.


In the compounds of this invention, carbon atoms bonded to four non-identical substituents are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof. The syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or
30 intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods

known in the art. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art. Each of the asymmetric carbon atoms, when present in the compounds of this invention, may be in one of two configurations (R or S) and both are within the scope of the present invention.

5

Compounds


The invention provides a compound of the general formulae (I) or (II):




10

wherein:

A is a member selected from the group consisting of:





R^{1a} , R^{1b} , R^{1d} , and R^{1e} are each independently a H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, aryl, $-\text{C}_{1-6}$ alkylaryl, $-(\text{CH}_2)_{1-6}\text{NR}_a\text{C}(=\text{O})\text{C}_{1-6}$ alkyl, $-(\text{CH}_2)_{1-6}\text{C}(=\text{O})\text{OH}$, $-(\text{CH}_2)_{1-6}\text{C}(=\text{O})\text{OC}_{1-6}$ alkyl, or $-(\text{CH}_2)_{1-6}\text{C}(=\text{O})\text{NR}_a\text{R}_b$; or R^{1a} and R^{1b} or R^{1a} and R^{1c} or R^{1a} and R^{1d} or R^{1d} and R^{1e} taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein R^{1a} , R^{1b} , R^{1d} , or R^{1e} is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylideneamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidiny, piperaziny, pyrrolidiny, aryl, morpholiny, and thiomorpholinyldioxide;


R^{1c} is H, C_{1-6} alkyl or C_{3-8} cycloalkyl;

R^{2a} , R^{2b} and R^{2c} are each independently a H, $-\text{C}_{1-6}$ alkyl, $-\text{C}_{2-6}$ alkenyl, $-\text{C}_{2-6}$ alkynyl, $-\text{C}_{3-8}$ cycloalkyl, aryl, $-\text{C}_{1-6}$ alkylaryl, $-(\text{CH}_2)_{1-6}\text{NR}_a\text{C}(=\text{O})\text{C}_{1-6}$ alkyl, $-(\text{CH}_2)_{1-6}\text{C}(=\text{O})\text{OH}$, $-(\text{CH}_2)_{1-6}\text{C}(=\text{O})\text{OC}_{1-6}$ alkyl, or $-(\text{CH}_2)_{1-6}\text{C}(=\text{O})\text{NR}_a\text{R}_b$; or R^{2a} and R^{2b} or R^{1a} , as set forth above, and R^{2a} or R^{1a} , as set forth above, and R^{2b} taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein R^{2a} , R^{2b} or R^{2c} is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylideneamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidiny, piperaziny, pyrrolidiny, aryl, morpholiny, and thiomorpholinyldioxide;

R_a and R_b are independently H, $-\text{C}_{1-6}$ alkyl, $-\text{C}_{2-6}$ alkenyl, $-\text{C}_{2-6}$ alkynyl; or R_a and R_b taken together with the nitrogen to which they are attached form azetidiny,

pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and its oxidized forms, piperazinyl, 4-methyl-1-piperazinyl, morpholinylcarbaldehyde, piperazinylcarbaldehyde or thiomorpholinylcarbaldehyde and its oxidized forms;

5 Q is a member selected from the group consisting of:



R^1 is a H, Cl, F, Br, I, $-C_{1-6}$ alkyl, $-OC_{1-6}$ alkyl, $-OhaloC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, $-NR_aR_b$, or $-SC_{1-6}$ alkyl, where R_a and R_b are as set forth above;

10

R^2 is a H, Cl, F, I, Br, $-OC_{1-6}$ alkyl or $-NR_aR_b$, where R_a and R_b are as set forth above;

R^3 , R^4 , R^5 , R^6 and R^7 are each H, -F, -Cl or -Br, OC_{1-6} alkyl, $-OhaloC_{1-6}$ alkyl, $-NR_aR_b$;

15 Y is CH or N;

X is O or S;

and


20

R is, in each occurrence, independently, H, -Cl, -Br, -I, -F, $-C_{1-6}$ alkyl, $-C_3$ -cycloalkyl, $-C_{0-6}$ alkyl- OC_{1-6} alkyl, $-C_{0-6}$ alkyl- $O(CH_2)_{1-4}$ -COOH, $-C_{0-6}$ alkyl- $O(CH_2)_{1-4}$ - $C(=O)OC_{1-6}$ alkyl, $-C_{0-6}$ alkylCOOH, $-C_{0-6}$ alkylCO₂ C_{1-6} alkyl, $-C_{0-6}$ alkyl OC_{1-6} alkyl, $-C_{1-6}$ alkylOH, $-C_{0-6}$ alkylCONH₂, $-C_{0-6}$ alkylNH₂,
 25 $-C_{0-6}$ alkylNH(C_{1-6} alkyl) or $-C_{0-6}$ alkylN(C_{1-6} alkyl)₂,

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

The invention further provides compounds of formulae (I) or (II) as set forth above, wherein:

A is a member selected from the group consisting of:



R^{1b} and R^{2a} are each a C_{1-6} alkyl or C_{3-8} cycloalkyl;

R is a $-Cl$, $-Br$, $-I$ or $-F$;

10 R^1 is a H , $-OMe$, OCF_3 , NH_2 , $NHMe$, NMe_2 , $-Cl$, $-Br$, $-I$ or $-F$;

R^2 is a H , $-Cl$, $-Br$, $-I$, $-F$ or $-O-C_{1-6}alkyl$;


R^3 is a H , $-Cl$, $-Br$, $-I$, $-F$, $-O-C_{1-6}alkyl$, $-NH-C_{1-6}acyl$, $-NO_2$, $-NHSO_2-C_{1-4}alkyl$, $-CN$
 15 or $-O-(CH_2)_{1-4}-COOH$;

X is $-O-$ or $-S-$;

R^4 and R^5 are each independently H , $-Cl$, $-Br$, $-I$, $-F$ or $-O-C_{1-6}alkyl$;

20

Q is a member selected from the group consisting of:




17

R¹ are each independently a H, Me, OMe, OCF₃, NHMe, NMe₂, -Cl, -Br, -I or -F, and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

5 The invention further provides a compound of formula (I) or (II), as set forth above, wherein:

A is a member selected from the group consisting of:



R is a -Cl, -Br, -I or -F;

R¹ is a H, -Cl, -Br, -I or -F;

15

R² is a H, -Cl, -Br, -I, -F or -O-C₁₋₆alkyl;

R³ is a H, -Cl, -Br, -I, -F or -O-C₁₋₆alkyl;


R⁴ is a H, -Cl, -Br, -I, -F, -O-C₁₋₆alkyl, -NH-C₁₋₆acyl, -NO₂, -NHSO₂-C₁₋₄alkyl, -CN and -O-(CH₂)₁₋₄-COOH;

X is -O- or -S-;

R⁶ and R⁷ are each independently a H, -Cl, -Br, -I, -F or -O-C₁₋₆alkyl;

5


Q is a member selected from the group consisting of:



R¹ is a H, -Cl, -Br, -I or -F,

10 and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.


The following compounds and their analogs can be synthesized by procedures similar to those described in the examples:



15

wherein:

A is a member selected from the group consisting of:



R^1 is a H, -F, -Cl, -OMe, -Me, -OCF₃, -SO₂Me, -NMe₂, or -SMe;

5 R^2 is a H, Cl, F, -OMe or -NMe₂;


R^3 is a H, Cl, F, -OMe or -NMe₂

R^4 is a H, -F, -Cl or -Br; -OMe, and

R is a -F, -Cl, or -Br,

10 and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

According to the invention, the quinazolinone compounds may exist in equilibrium with hydrate compounds (uncyclized) as set forth below:



5 The invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives of the compounds of the invention, as set forth herein. The compounds of the invention can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates, solvates and prodrug

10 derivatives of such isomers and tautomers.

 The compounds of the invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of the invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the

15 processes of isolation and purification.

A number of methods are useful for the preparation of the salts of the compounds as described above and are known to those skilled in the art. For example, the free acid or free base form of a compound of one of the formulae above can be reacted with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.

10 The invention also encompasses prodrug derivatives of the compounds contained herein. The term "prodrug" refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug. Prodrugs are variations or derivatives of the compounds of the invention which have groups
15 cleavable under metabolic conditions. Prodrugs become the compounds of the invention which are pharmaceutically active *in vivo*, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug compounds of the invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the
20 organism, and indicating the number of functionalities present in a precursor-type form. Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA,
25 1992). Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative. Moreover, the prodrug derivatives of the invention may be combined
30 with other features herein taught to enhance bioavailability.

The compounds of the present invention may also be used alone or in combination or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of the invention may be coadministered along with other compounds typically prescribed for these
5 conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin. The compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic
10 therapy and/or reduce the time to reperfusion. These compounds may also allow for reduced doses of the thrombolytic agents to be used and therefore minimize potential hemorrhagic side-effects. The compounds of the invention can be utilized *in vivo*, ordinarily in mammals such as primates (e.g. humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

15 The biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the *in vitro* protease activity assays and *in vivo* studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.

20 Diagnostic applications of the compounds of the invention will typically utilize formulations in the form of solutions or suspensions. In the management of thrombotic disorders the compounds of the invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the
25 like, or incorporated into shaped articles. Subjects in need of treatment (typically mammalian) using the compounds of the invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition,
30 the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.

Preparation of Compounds

The compounds of the present invention may be synthesized by standard organic chemical synthetic methods as described and referenced in standard textbooks. These methods are well known in the art. See, e.g., Morrison and Boyd,
5 "Organic Chemistry", Allyn and Bacon, Inc., Boston, 1959, et seq.


Starting materials used in any of these methods are commercially available from chemical vendors such as Aldrich, Sigma, Nova Biochemicals, Bachem Biosciences, and the like, or may be readily synthesized by known procedures.

Reactions are carried out in standard laboratory glassware and reaction
10 vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.

During the synthesis of these compounds, the functional groups of the substituents are optionally protected by blocking groups to prevent cross reaction during coupling procedures. Examples of suitable blocking groups and their use are
15 described in "The Peptides: Analysis, Synthesis, Biology", Academic Press, Vol. 3 (Gross, *et al.*, Eds., 1981) and Vol. 9 (1987), the disclosures of which are incorporated herein by reference.


Non-limiting exemplary synthesis schemes are outlined directly below, and specific steps are described in the Examples. The reaction products are isolated and
20 purified by conventional methods, typically by solvent extraction into a compatible solvent. The products may be further purified by column chromatography or other appropriate methods.

SCHEME 1




5

SCHEME 2




SCHEME 3




5

SCHEME 4




SCHEME 5




10


SCHEME 6



SCHEME 7

Example 1

5 **2-{4-[(dimethylamino)iminomethyl]phenyl}-6-chloro-3-(5-chloro(2-pyridyl))-3-hydroquinazolin-4-one (4A)**

Step 1:

To a solution of 2-amino-5-chloropyridine (0.32 gm, 2.5 mmol) in anhydrous THF
 10 (20 mL) at -78°C was added a 0.5M solution of $\text{KN}(\text{SiMe}_3)_2$ in toluene (10.2 mL).
 The mixture was stirred at -78°C for 30 min before 5-chloro-isatoicanhydride (0.5
 gm, 2.5 mmol) was added. The mixture was stirred at -78°C and then warmed up to
 room temperature and left overnight. The mixture was concentrated and diluted with
 EtOAc (30 mL). The organic solution was washed with sat. NH_4Cl solution, dried
 15 and evaporated to give compound 1A (0.71 gm, 100%). MS found for $\text{C}_{12}\text{H}_9\text{Cl}_2\text{N}_3\text{O}$
 ($\text{M}+\text{H}^+$): 282.

Step 2:

To a solution of compound 1A (710 mg, 2.52 mmol) in CH₂Cl₂ (10 mL) and pyridine (0.61 mL) was added 4-cyano-benzoylchloride (417 mg, 2.52 mmol). After stirring at ambient temperatures overnight, the mixture was concentrated and the residue was triturated with CH₂Cl₂. The solid material was filtered and dried to get 683 mg (66% yield) of compound 2A. MS found for C₂₀H₁₂Cl₂N₄O₂ (M+H)⁺: 411.0.

Step 3:


To a solution of compound 2A (100mg, 0.20mmol) in 10% Et₃N/pyridine (10 mL) at 0°C was bubbled dry H₂S gas to saturation. The mixture was stirred at ambient temperatures overnight. The volatile was removed to dryness. The residue was suspended in anhydrous acetone (10 mL), followed by addition of MeI (1 mL). The reaction mixture was refluxed for 1 hour. The solvent was removed by rotary evaporation. The residue was dissolved in anhydrous MeOH (5 mL). A mixture of dimethylamine (0.5 mL, 2N in THF) and AcOH (60 µL) was added to the solution. The resulting mixture was refluxed for 1 hour, concentrated and subjected to RP-HPLC purification to give the title compound 3A. MS found for C₂₂H₁₉Cl₂N₅O₂ (M+H)⁺: 456.

Step 4:

To a solution of compound 3A (15 mg) in 2 mL MeOH was added acetylchloride (20 µL). The mixture was refluxed for 4 hours, concentrated and purified by RP-HPLC to afford compound the title compound 4A. MS found for C₂₂H₁₇Cl₂N₅O (M+H)⁺: 438.0.

Example 2


6-chloro-3-(5-chloro(2-pyridyl))-2-[4-(1-methyl(2-imidazolin-2-yl))phenyl]-3-hydroquinazolin-4-one



The titled compound was made by the procedure similar to that described in example 1. MS found for $C_{23}H_{17}Cl_2N_5O$ ($M+H$)⁺: 450.1.

5 Example 3


2-{4-[(dimethylamino)iminomethyl]phenyl}-3-(5-chloro(2-pyridyl))-6-methoxy-3-hydroquinazolin-4-one



10 The titled compound was made by the procedure similar to that described in example 2. MS found for $C_{23}H_{20}ClN_5O_2$ ($M+H$)⁺: 434.

Example 4

3-(5-chloro(2-pyridyl))-2-[4-(iminopiperidylmethyl)phenyl]-3-hydroquinazolin-4-one



The titled compound was made by the procedure similar to that described in example 1 except the following two steps.

20 Step 3:

To a solution of N-{2-[N-(5-chloro(2-pyridyl))carbamoyl]phenyl}(4-cyanophenyl)-carboxamide (prepared by the procedure similar to that described in step 1 and 2,


example 1) in ethanol (10mL) at 0°C was bubbled dry HCl gas to saturation. The mixture was stirred at ambient temperatures overnight, and the conversion was complete. The solvent was removed to dryness. The residue was mixed with piperidine. The resulting mixture was refluxed for 1 hour, concentrated and
5 subjected to RP-HPLC purification to give N-{2-[N-(5-chloro(2-pyridyl))carbamoyl]phenyl}[4-(iminopiperidylmethyl)phenyl]carboxamide.

Step 4:

To a solution of N-{2-[N-(5-chloro(2-pyridyl))carbamoyl]phenyl}[4-(iminopiperidylmethyl)-
10 (iminopiperidylmethyl)-phenyl]carboxamide in EtOH was bubbled HCl gas and the mixture was refluxed for 4 hours and concentrated and purified by RP-HPLC to get the titled compound 3-(5-chloro(2-pyridyl))-2-[4-(iminopiperidylmethyl)phenyl]-3-hydroquinazolin-4-one. MS found for $C_{20}H_{11}ClN_4O$ ($M+1$)⁺ 359.


15

SCHEME 8



Example 5

2-{4-[(dimethylamino)iminomethyl]phenyl}-6,8-dichloro-3-(5-chloro(2-
20 pyridyl))-3-hydroquinazolin-4-one (4B)



Step 1:

Compound **1B** was prepared by the same procedure as described in step 1, example

5 1. MS found for $C_{12}H_9Cl_2N_3O$ ($M+H$)⁺: 282.

Step 2:

To a solution of compound **1B** (630 mg, 1.99 mmol) in CH_2Cl_2 (10 mL) and

pyridine (0.48 mL) was added 4-cyano-benzoylchloride (396 mg, 2.4 mmol). After

10 stirring at 35°C for two hours and at room temperature overnight, two products

(compound **2B** and **5**) were formed. The mixture was concentrated and the residue

was triturated with CH_2Cl_2 . The solid material was filtered and dried to give 330 mg

of compound **5** (37%). MS found for $C_{20}H_9Cl_3N_4O$ ($M+H$)⁺: 427.0. The filtrate was

concentrated and the residue was triturated again with CH_2Cl_2 . The solid was filtered

15 to give 260 mg of compound **2B** (30%). MS found for $C_{20}H_{11}Cl_3N_4O_2$ ($M+H$)⁺:

445.0.

Step 3:

To a solution of compound **5** (100 mg, 0.20mmol) in 10% Et_3N /pyridine (10 mL) at

20 0°C was bubbled dry H_2S gas to saturation. The mixture was stirred at ambient

temperatures overnight, and the conversion was complete. The solvent was removed

to dryness. The residue was suspended in anhydrous acetone (10 mL), followed by

addition of MeI (1 mL). The reaction mixture was refluxed for 1 hour. The solvent


was removed by rotary evaporation. The residue was dissolved in anhydrous MeOH

25 (5 mL). A mixture of dimethylamine (0.5 mL, 2N in THF) and AcOH (60 μ L) was

added to the solution. After stirred at reflux for 1 hour, the mixture was concentrated

and subjected to RP-HPLC purification to give the title compound **4B**. MS found for


$C_{22}H_{16}Cl_3N_5O$ ($M+H$)⁺: 472.

Example 6**6,8-dichloro-3-(5-chloro(2-pyridyl))-2-[4-(iminopyrrolidinylmethyl)phenyl]-3-hydroquinazolin-4-one**

The title compound was prepared according to the procedure described in example 5. MS found for $C_{24}H_{18}Cl_3N_5O$ ($M+H$)⁺: 498.


Example 7

10 **6,8-dichloro-3-(5-chloro(2-pyridyl))-2-[4-(1-methyl(2-imidazolin-2-yl))phenyl]-3-hydroquinazolin-4-one**



The title compound was prepared according to the procedure described in example 5. MS found for $C_{23}H_{16}Cl_3N_5O$ ($M+H$)⁺: 484.


15

Example 8**4-[3-(4-chlorophenyl)-4-oxo-3-hydroquinazolin-2-yl]benzenecarboxamide**

20 The titled compound was made by the procedure similar to that described in example 5 except the following one step.

Step 3:


To a solution of 4-[3-(4-chlorophenyl)-4-oxo-3-hydroquinazolin-2-yl]benzenecarbonitrile (prepared by the procedure similar to that described in step 1 and 2, example 5) in EtOH at 0°C was bubbled dry HCl gas to saturation. The mixture was stirred at ambient temperatures overnight, and the conversion was complete. The solvent was removed to dryness. The residue was mixed with ammonia acetate. The reaction mixture was refluxed for 1 hour, concentrated and subjected to RP-HPLC purification to give the title compound 4-[3-(4-chlorophenyl)-4-oxo-3-hydroquinazolin-2-yl]benzenecarboxamide. MS found for $C_{21}H_{15}ClN_4O$ (M+H)⁺: 375.

Example 9**3-(4-chlorophenyl)-2-[4-(iminopiperidylmethyl)phenyl]-3-hydroquinazolin-4-one**


The titled compound was made by the procedure similar to that described in example 8. MS found for $C_{26}H_{23}ClN_4O$ (M+H)⁺: 443.

Example 10


20 **2-[4-[(dimethylamino)iminomethyl]phenyl]-3-(4-chlorophenyl)-3-hydroquinazolin-4-one**



The titled compound was made by the procedure similar to that described in example 8. MS found for $C_{23}H_{19}ClN_4O$ (M+H)⁺: 403.


Example 11**3-(4-chlorophenyl)-2-[4-(iminopyrrolidinyl)methyl]phenyl]-3-hydroquinazolin-4-one**

- 5 The titled compound was made by the procedure similar to that described in example 8. MS found for $C_{25}H_{21}ClN_4O$ ($M+H$)⁺: 429.

Example 12**2-{4-[(dimethylamino)iminomethyl]phenyl}-3-(4-fluorophenyl)-3-hydroquinazolin-4-one**


The titled compound was made by the procedure similar to that described in example 8. MS found for $C_{23}H_{19}FN_4O$ ($M+H$)⁺: 387.

15

SCHEME 9

Example 13

2-{4-[(dimethylamino)iminomethyl](2-thienyl)}-6-chloro-3-(5-chloro(2-pyridyl))-3-hydroquinazolin-4-one (5C)



5 Step 1:

To a stirred solution of 4-bromo-2-thiophenecarboxaldehyde (4.5 g, 23 mmol) in anhydrous DMF (25 mL) were added CuCN (6.4 g, 71 mmol) and CuI (2.0 g, 10 mmol). The slurry was refluxed for 1 hr. It was diluted with 300 mL of DMF and filtered through a celite-silica bed to remove the solid. The filtrate was concentrated in vacuo. The residue was washed with hot chloroform (200 mL X4). The chloroform extracts were decanted, combined and washed with water. The chloroform solution was dried over MgSO₄ and concentrated in vacuo to give 1C (2.2 g, 71%) as a solid. MS found for C₆H₃NOS (M+H)⁺ 138.

15 Step 2:

To a stirred solution of 1C (2.2 g, 16 mmol) in 20 mL acetone were added tBuOH (150 mL) and 2-methylbutene (30 mL). To the mixture was then added a solution of NaClO₂ (13 g, 150 mmol) and NaH₂PO₄ (12 g, 100 mmol) in 100 mL water at room temperature. The mixture was stirred for 1 hr. It was acidified with 1N HCl till pH=1. The mixture was rotovaped to remove organic solvents. The residue was extracted with EtOAc (250 mL X4). The organic extracts were dried over MgSO₄ and concentrated in vacuo to afford 2C (2.8 g, 99%) as a white solid. MS found for C₆H₃NO₂S (M+Na)⁺ 176.

25 Step 3:

To a stirred solution of 2C (153 mg, 1 mmol) and 1A (see Scheme 7, 240 mg, 1.1 mmol) in 3 mL pyridine were added DMAP (cat.) and POCl₃ (0.24 mL, 2.5 mmol) at 0°C. The reaction was stirred for 1 hr and quenched with ice water. It was diluted with EtOAc (150 mL) and washed with water (X3). The organic phase was

dried, concentrated and purified with flash column to afford **3C** (30%) and **4C** (30%). MS found for **3C** $C_{18}H_{10}Cl_2N_4O_2S$ $(M+H)^+$ 417. MS found for **4C** $C_{18}H_8Cl_2N_4OS$ $(M+H)^+$ 399.


5 Step 4:

To a solution of compound **4C** (40 mg, 0.1 mmol) in 10% Et_3N /dioxane (5 mL) at room temperature was bubbled H_2S gas to saturation. The mixture was stirred for overnight and then evaporated in vacuo. The dry residue was then taken into 10 mL dry acetone and MeI (0.5 mL). The mixture was refluxed for 1 hr and
10 evaporated in vacuo to dryness. It was dissolved in dry MeOH (4 mL). This solution was added to a pre-mixed solution of dimethylamine (0.5 mL, 2N in THF) and HOAc (0.2 mL) in 2 mL dry MeOH. The mixture was refluxed for 1 hr, evaporated in vacuo and subjected to RP-HPLC purification to yield the title compound **5C**. MS found for **5C** $C_{20}H_{15}Cl_2N_5OS$ $(M+H)^+$ 444.

15

Example 14

6-Chloro-3-(5-chloro(2-pyridyl))-2-[4-(1-methyl(2-imidazolin-2-yl))(2-thienyl)]-3-hydroquinazolin-4-one.




20 The title compound was prepared by the procedure similar to that described in Example 13. MS found for $C_{21}H_{15}Cl_2N_5OS$ $(M+H)^+$ 456.

Example 15

6-Chloro-3-(5-chloro(2-pyridyl))-2-{4-[(ethylmethylamino)iminomethyl]}(2-thienyl))-3-hydroquinazolin-4-one.


25



The title compound was prepared by the procedure similar to that described in Example 13. MS found for $C_{21}H_{17}Cl_2N_5OS$ $(M+H)^+$ 458.

Example 16

- 5 **6-Chloro-3-(5-chloro(2-pyridyl))-2-{4-[imino(methylpropylamino)methyl](2-thienyl)}-3-hydroquinazolin-4-one**




The title compound was prepared by the procedure similar to that described in Example 13. MS found for $C_{22}H_{19}Cl_2N_5OS$ $(M+H)^+$ 472.

10

Example 17


- 2-{4-[(Butylmethylamino)iminomethyl](2-thienyl)}-6-chloro-3-(5-chloro(2-pyridyl))-3-hydroquinazolin-4-one**



- 15 The title compound was prepared by the procedure similar to that described in Example 13. MS found for $C_{23}H_{21}Cl_2N_5OS$ $(M+H)^+$ 486.

Example 18


- 6-Chloro-3-(5-chloro(2-pyridyl))-2-(4-{imino[(2-methoxyethyl)methylamino]methyl}(2-thienyl))-3-hydroquinazolin-4-one**



The title compound was prepared by the same procedure similar to that described in Example 13. MS found for $C_{22}H_{19}Cl_2N_5O_2S$ $(M+H)^+$ 488.

Example 19


2-[4-({[2-(Dimethylamino)ethyl]methylamino}iminomethyl)(2-thienyl)]-6-chloro-3-(5-chloro(2-pyridyl))-3-hydroquinazolin-4-one



The title compound was prepared by the same procedure similar to that described in Example 13. MS found for $C_{23}H_{22}Cl_2N_6OS$ $(M+H)^+$ 501.

Example 20

10 2-[4-({[3-(Dimethylamino)propyl]methylamino}iminomethyl)(2-thienyl)]-6-chloro-3-(5-chloro(2-pyridyl))-3-hydroquinazolin-4-one




The title compound was prepared by the procedure similar to that described in Example 13. MS found for $C_{24}H_{24}Cl_2N_6OS$ $(M+H)^+$ 515.

15

Example 21


6-Chloro-3-(5-chloro(2-pyridyl))-2-[4-(iminopyrrolidinylmethyl)(2-thienyl)]-3-hydroquinazolin-4-one



20 The title compound was prepared by the procedure similar to that described in Example 13. MS found for $C_{22}H_{17}Cl_2N_5OS$ $(M+H)^+$ 470.

Example 22


6-Chloro-3-(5-chloro(2-pyridyl))-2-[4-(iminopiperidylmethyl)(2-thienyl)]-3-hydroquinazolin-4-one



- 5 The title compound was prepared by the procedure similar to that described in Example 13. MS found for $C_{23}H_{19}Cl_2N_5OS$ ($M+H$)⁺ 484.


Example 23

6-chloro-3-(5-chloro(2-pyridyl))-2-{4-[imino(4-methylpiperazinyl)methyl](2-thienyl)}-3-hydroquinazolin-4-one




The title compound was prepared by the procedure similar to that described in Example 13. MS found for $C_{23}H_{20}Cl_2N_6OS$ ($M+H$)⁺ 499.

15

SCHEME 10

Example 24

5-(5-chloro(2-pyridyl))- 1-methyl-6-(4-dimethylaminoiminomethyl)phenyl-5-hydropyrazolo[5,4-d]pyrimidin-4-one.



5 Step1:

A solution of 1-methyl-5-nitro-1*H*-pyrazole-4-carboxylic acid (340 mg) in 10 mL of dichloromethane was treated with 3 mL of (COCl)₂ and 2 drops of DMF at rt for 2h. The volatile was evaporated and the residue was dissolved in 15 mL of dichloromethane. To the solution was added 256 mg (1 equiv) of 2-amino-5-chloropyridine and 2 mL of pyridine. The mixture was stirred at rt overnight and diluted with EtOAc, washed with water and dried over Na₂SO₄, filtered and evaporated to give 1-methyl-5-nitro-1*H*-pyrazole-4-*N*-(5-chloro(2-pyridyl))carboxamide.

15 Step 2:

A mixture of 1-methyl-5-nitro-1*H*-pyrazole-4-*N*-(5-chloro(2-pyridyl))carboxamide (281 mg, 1 mmol) and SnCl₂·2H₂O (675 mg, 3 equiv) in 15 mL of EtOAc was stirred at reflux for 2 h. After cooling to rt, the mixture was diluted with EtOAc and washed with saturated NaHCO₃ and dried over Na₂SO₄, filtered and evaporated to give 1-methyl-5-amino-1*H*-pyrazole-4-*N*-(5-chloro(2-pyridyl))carboxamide (**1D**).


Step 3:

A mixture of 1-methyl-5-amino-1*H*-pyrazole-4-*N*-(5-chloro(2-pyridyl))carboxamide (170 mg, 0.68 mmol) and 4-cyanobenzoic acid (100 mg, 1equiv) in 2 mL of pyridine was treated with 63 μ L of POCl₃ at rt overnight. The reaction was quenched with water, diluted with EtOAc and washed with water, dried over Na₂SO₄, filtered and evaporated. The crude mixture was subjected to flash chromatography to give 5-(5-chloro(2-pyridyl))-1-methyl-6-(4-cyano)phenyl-5-hydropyrazolo[5,4-d]pyrimidin-4-one (**2D**).


Step 4:

A solution of 5-(5-chloro(2-pyridyl))-1-methyl-6-(4-cyano)phenyl-5-hydropyrazolo[5,4-d]pyrimidin-4-one (36 mg) in anhydrous pyridine (5 mL) and triethyl amine (1 mL) was saturated with hydrogen sulfide gas at 0°C. The mixture was stirred at rt overnight. After concentration, the residue was dissolved in anhydrous acetone (5 mL) and iodomethane (0.5 mL) was added. The mixture was refluxed for 2 hrs. After concentration the residue was dissolved in anhydrous methanol (5 mL) and a premixed solution of 2M dimethylamine in THF (0.5 mL) and acetic acid in 3 mL of MeOH were added. The mixture was refluxed for 15 min. After concentration, the crude residue was purified by RP-HPLC to give the target compound (3D) as a TFA salt. MS found $C_{20}H_{18}ClN_7O$ ($M+H$)⁺=408.

SCHEME 11

Example 25

2-{4-(methylaminomethyl)phenyl}-6-chloro-3-(5-chloro(2-pyridyl))-3-hydroquinazolin-4-one.



Step 1:

A mixture of 4-chloromethyl benzoyl chloride (335 mg, 1.77mmol, 1 equiv) and 1A (see example 1, 500mg, 1.77mmol, 1 equiv) in anhydrous tetrahydrofuran (30mL)

was stirred at rt overnight. The volatile was evaporated and the crude residue was triturated by ethyl acetate to give N-(5-chloro-2-pyridinyl)-2-(4-chloromethylphenylcarbonyl)amino-5-chlorophenylcarboxamide (2E, 630 mg, 91%).

5

Step 2:

A mixture of N-(5-chloro-2-pyridinyl)-2-(4-chloromethylphenylcarbonyl)amino-5-chloro-phenylcarboxamide (300 mg, 0.69mmol), methylamine (2M in THF, 5 mL) in anhydrous N,N-dimethyl formamide (5 mL) was stirred at rt overnight. After
10 concentration, the crude residue was triturated with ethyl acetate to give N-(5-chloro-2-pyridinyl)-2-(4-methylaminomethylphenyl-carbonyl)amino-5-chlorophenylcarboxamide (3E).

Step 3:

15 A suspension of N-(5-chloro-2-pyridinyl)-2-(4-methylaminomethylphenyl carbonyl)amino-5-chlorophenylcarboxamide (42 mg, 0.1 mmol) in 5 mL of anhydrous ether was treated with Et₃OBf₄ (1 M in dichloromthane, 1 mL, 10 equiv) at rt overnight. The volatile was evaporated and the crude residue was subjected to RP-HPLC to give 2-{4-(methylaminomethyl)phenyl}-6-chloro-3-(5-chloro(2-
20 pyridyl))-3-hydroquinazolin-4-one (4E). MS found C₂₅H₂₂Cl₂N₅O₂ (M+H)⁺=478.

Compositions and Formulations

Compositions or formulations of the compounds of the invention are prepared for storage or administration by mixing the compound having a desired
25 degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., (A.R. Gennaro edit. 1985). Such materials are nontoxic to the
30 recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic

acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other
5 carbohydrates including cellulose or its derivatives, glucose, mannose or dextrans, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween®, Plurionics® or polyethyleneglycol.

Dosage formulations of the compounds of the invention to be used for
10 therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of the invention typically will be between about 3 and about 11, more preferably from about 5 to about 9 and most
15 preferably from about 7 to about 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally or
20 intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches. The compounds of the invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for
25 example, Silastic, silicone rubber or other polymers commercially available.

The compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.

30 The compounds of the invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting

moieties, to which the compound molecules are coupled. The compounds of the invention may also be coupled with suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or
5 polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the factor Xa inhibitors of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals,
10 polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.

Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or
15 vial having a stopper pierceable by hypodermic injection needle.

Therapeutically effective dosages may be determined by either *in vitro* or *in vivo* methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range
of therapeutically effective dosages will naturally be influenced by the route of
20 administration, the therapeutic objectives, and the condition of the patient. For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be individually determined for each inhibitor by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to titer the dosage and modify the
25 route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be within the ambit of one skilled in the art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.

30 A typical dosage of the compounds and compositions of the invention range from about 0.001 mg/kg to about 1000 mg/kg, preferably from about 0.01 mg/kg to

about 100 mg/kg, and more preferably from about 0.10 mg/kg to about 20 mg/kg. Advantageously, the compounds of the invention may be administered several times daily. Other dosage regimens may also be useful (e.g. single daily dose and/or continuous infusion).

5 Typically, about 0.5 to about 500 mg of a compound or mixture of compounds of the invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor, etc., as called for by accepted pharmaceutical practice. The amount of active ingredient in these compositions is
10 such that a suitable dosage in the range indicated is obtained.

Typical adjuvants which may be incorporated into tablets, capsules and the like are a binder such as acacia, corn starch or gelatin, and excipient such as microcrystalline cellulose, a disintegrating agent like corn starch or alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose or lactose,
15 or a flavoring agent. When a dosage form is a capsule, in addition to the above materials it may also contain a liquid carrier such as water, saline, a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or
20 suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.

The preferred compounds of the present invention are characterized by their
25 ability to inhibit thrombus formation with acceptable effects on classical measures of coagulation parameters, platelets and platelet function, and acceptable levels of bleeding complications associated with their use. Conditions characterized by undesired thrombosis would include those involving the arterial and venous vasculature.

30 With respect to the coronary arterial vasculature, abnormal thrombus formation characterizes the rupture of an established atherosclerotic plaque which is

the major cause of acute myocardial infarction and unstable angina, as well as also characterizing the occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA).

With respect to the venous vasculature, abnormal thrombus formation
5 characterizes the condition observed in patients undergoing major surgery in the lower extremities or the abdominal area who often suffer from thrombus formation in the venous vasculature resulting in reduced blood flow to the affected extremity and a predisposition to pulmonary embolism. Abnormal thrombus formation further characterizes disseminated intravascular coagulopathy commonly occurs within both
10 vascular systems during septic shock, certain viral infections and cancer, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure.

The compounds of the invention are useful for the treatment or prophylaxis
15 of those diseases which involve the production and/or action of factor Xa/prothrombinase complex. The compounds of this present invention, selected and used as disclosed herein, find utility as a diagnostic or therapeutic agent for preventing or treating a condition in a mammal characterized by undesired thrombosis or a disorder of coagulation. Disease states treatable or preventable by

20 the administration of compounds of the invention include, without limitation, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature, disseminated intravascular coagulopathy, the treatment of reocclusion or restenosis of reperfused coronary arteries, thromboembolic complications of
25 surgery and peripheral arterial occlusion, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure, hemorrhagic stroke, renal dialysis, blood oxygenation, and cardiac catheterization.

30 Accordingly, the invention provides a method for preventing or treating a condition in a mammal characterized by undesired thrombosis which administers to

a mammal a therapeutically effective amount of a compound of the invention, as described herein. Conditions for prevention or treatment include, for example, (a) the treatment or prevention of any thrombotically mediated acute coronary syndrome including myocardial infarction, unstable angina, refractory angina, 5 occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, (b) the treatment or prevention of any thrombotically mediated cerebrovascular syndrome including embolic stroke, thrombotic stroke or transient ischemic attacks, (c) the treatment or prevention of any thrombotic syndrome occurring in the venous system including deep venous thrombosis or pulmonary 10 embolus occurring either spontaneously or in the setting of malignancy, surgery or trauma, (d) the treatment or prevention of any coagulopathy including disseminated intravascular coagulation (including the setting of septic shock or other infection, surgery, pregnancy, trauma or malignancy and whether associated with multi-organ failure or not), thrombotic thrombocytopenic purpura, thromboangiitis obliterans, or 15 thrombotic disease associated with heparin induced thrombocytopenia, (e) the treatment or prevention of thrombotic complications associated with extracorporeal circulation (e.g. renal dialysis, cardiopulmonary bypass or other oxygenation procedure, plasmapheresis), (f) the treatment or prevention of thrombotic complications associated with instrumentation (e.g. cardiac or other intravascular 20 catheterization, intra-aortic balloon pump, coronary stent or cardiac valve), and (g) those involved with the fitting of prosthetic devices.

Anticoagulant therapy is also useful to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus the compounds of the invention can be added to or contacted with any medium 25 containing or suspected to contain factor Xa and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material such as vascular grafts, stents, orthopedic prostheses, cardiac stents, valves and prostheses, extra corporeal circulation systems and the like.

Thus, the compounds of the invention also find utility in a method for 30 inhibiting the coagulation of biological samples by administration of a compound of the invention.

BIOLOGICAL ACTIVITY EXAMPLES

Evaluation of the compounds of the invention is guided by in vitro protease activity assays (see below) and in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters.

The compounds of the present invention are dissolved in buffer to give solutions containing concentrations such that assay concentrations range from about 0 to 100 μM . In the assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate is added to a solution containing test compound and the enzyme of interest and the residual catalytic activity of that enzyme is determined spectrophotometrically. The IC_{50} of a compound is determined from the substrate turnover. The IC_{50} is the concentration of test compound giving 50% inhibition of the substrate turnover. The compounds of the present invention desirably have an IC_{50} of less than about 500 nM in the factor Xa assay, preferably less than about 200 nM, and more preferred compounds have an IC_{50} of about 100 nM or less in the factor Xa assay. The compounds of the present invention desirably have an IC_{50} of less than about 4.0 μM in the prothrombinase assay, preferably less than 200 nM, and more preferred compounds have an IC_{50} of about 10 nM or less in the prothrombinase assay. The compounds of the present invention desirably have an IC_{50} of greater than about 1.0 μM in the thrombin assay, preferably greater than about 10.0 μM , and more preferred compounds have an IC_{50} of greater than about 100.0 μM in the thrombin assay.

Amidolytic Assays for determining protease inhibition activity

The factor Xa and thrombin assays are performed at room temperature, in 0.02 M Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl. The rates of hydrolysis of the para-nitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with inhibitor for 5 minutes at room temperature, and

were determined using the Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroaniline.

The prothrombinase inhibition assay is performed in a plasma free system with modifications to the method described by Sinha, U. *et al.*, *Thromb. Res.*, 75,
5 427-436 (1994). Specifically, the activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH. The assay consists of preincubation (5 minutes) of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Va (2 nM), phosphatidyl serine:phosphatidyl choline
10 (25:75, 20 μ M) in 20 mM Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl, 5 mM CaCl_2 and 0.1% bovine serum albumin. Aliquots from the complex-inhibitor mixture are added to prothrombin (1 nM) and Chromozym TH (0.1 mM). The rate of substrate cleavage is monitored at 405 nm for two minutes. Eight different concentrations of inhibitor are assayed in duplicate. A standard curve of thrombin
15 generation by an equivalent amount of untreated complex are used for determination of percent inhibition.

Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis

A rabbit deep vein thrombosis model as described by Hollenbach, S. *et al.*,
20 *Thromb. Haemost.* 71, 357-362 (1994), is used to determine the in-vivo antithrombotic activity of the test compounds. Rabbits are anesthetized with I.M. injections of Ketamine, Xylazine, and Acepromazine cocktail. A standardized protocol consists of insertion of a thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit. A non-occlusive
25 thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is used as a measure of the antithrombotic activity of the studied compounds. Test agents or control saline are administered through a marginal ear vein catheter. A femoral vein catheter is used for blood sampling prior to and during steady state infusion of test compound. Initiation of thrombus formation begins
30 immediately after advancement of the cotton thread apparatus into the central venous circulation. Test compounds are administered from time = 30 min to time =

150 min at which the experiment is terminated. The rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology. Blood samples are analyzed for changes in hematological and coagulation parameters.

5



Effects of Compounds in Rabbit Venous Thrombosis model

Administration of compounds in the rabbit venous thrombosis model demonstrates antithrombotic efficacy at the higher doses evaluated. There are no significant effects of the compound on the aPTT and PT prolongation with the
10 highest dose (100 $\mu\text{g/kg}$ + 2.57 $\mu\text{g/kg/min}$). Compounds have no significant effects on hematological parameters as compared to saline controls. All measurements are an average of all samples after steady state administration of vehicle or (D)-Arg-Gly-Arg-thiazole. Values are expressed as mean \pm SD.

15 Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It will be apparent
20 to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. All the patents, journal articles and other documents discussed or cited above are herein incorporated by reference.


WHAT IS CLAIMED IS:

1. A compound of the general formulae (I) or (II):



wherein:

A is a member selected from the group consisting of:



R^{1a} , R^{1b} , R^{1d} , and R^{1e} are each independently a H, C_{1-6} alkyl, C_{2-6} alkenyl,

C₂₋₆alkynyl, C₃₋₈cycloalkyl, aryl, -C₁₋₆alkylaryl, -(CH₂)₁₋₆NR_aC(=O)C₁₋₆alkyl, -(CH₂)₁₋₆C(=O)OH, -(CH₂)₁₋₆C(=O)OC₁₋₆alkyl, or -(CH₂)₁₋₆C(=O)NR_aR_b; or R^{1a} and R^{1b} or R^{1a} and R^{1c} or R^{1a} and R^{1d} or R^{1d} and R^{1e} taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8
 5 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein R^{1a}, R^{1b}, R^{1d}, or R^{1e} is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl,
 10 morpholinyl, and thiomorpholinyldioxide;


R^{1c} is H, C₁₋₆alkyl or C₃₋₈cycloalkyl;

R^{2a}, R^{2b} and R^{2c} are each independently a H, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl, -C₃₋₈cycloalkyl, aryl, -C₁₋₆alkylaryl, -(CH₂)₁₋₆NR_aC(=O)C₁₋₆alkyl, -(CH₂)₁₋₆C(=O)OH, -(CH₂)₁₋₆C(=O)OC₁₋₆alkyl, or -(CH₂)₁₋₆C(=O)NR_aR_b; or R^{2a} and R^{2b} or R^{1a}, as set forth above, and R^{2a} or R^{1a}, as set forth above, and R^{2b} taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine
 15 group which, optionally, contains at least one other heteroatom of N, O or S; wherein R^{2a}, R^{2b} or R^{2c} is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide;

25

R_a and R_b are independently H, -C₁₋₆alkyl, -C₂₋₆alkenyl, -C₂₋₆alkynyl; or R_a and R_b taken together with the nitrogen to which they are attached form azetidiny, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and its oxidized forms, piperazinyl, 4-methyl-1-piperazinyl, morpholinylcarbaldehyde,
 30 piperazinylcarbaldehyde or thiomorpholinylcarbaldehyde and its oxidized forms;

Q is a member selected from the group consisting of:



R^1 is a H, Cl, F, Br, I, $-C_{1-6}$ alkyl, $-OC_{1-6}$ alkyl, $-OhaloC_{1-6}$ alkyl, $-SO_2C_{1-6}$ alkyl, $-NR_aR_b$, or $-SC_{1-6}$ alkyl, where R_a and R_b are as set forth above;

R^2 is a H, Cl, F, I, Br, $-OC_{1-6}$ alkyl or $-NR_aR_b$, where R_a and R_b are as set forth above;

R^3 , R^4 , R^5 , R^6 and R^7 are each H, -F, -Cl, or -Br, OC_{1-6} alkyl, $-OhaloC_{1-6}$ alkyl, $-NR_aR_b$;

Y is CH or N;

X is O or S;


and

R is, in each occurrence, independently, H, -Cl, -Br, -I, -F, $-C_{1-6}$ alkyl, $-C_{3-8}$ cycloalkyl, $-C_{0-6}$ alkyl- OC_{1-6} alkyl, $-C_{0-6}$ alkyl- $O(CH_2)_{1-4}$ -COOH, $-C_{0-6}$ alkyl- $O(CH_2)_{1-4}$ - $C(=O)OC_{1-6}$ alkyl, $-C_{0-6}$ alkylCOOH, $-C_{0-6}$ alkylCO₂ C_{1-6} alkyl, $-C_{0-6}$ alkylOC₁₋₆alkyl, $-C_{1-6}$ alkylOH, $-C_{0-6}$ alkylCONH₂, $-C_{0-6}$ alkylNH₂, $-C_{0-6}$ alkylNH(C_{1-6} alkyl) or $-C_{0-6}$ alkylN(C_{1-6} alkyl)₂,

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

2. A compound of claim 1, wherein:

A is a member selected from the group consisting of:



R^{1b} and R^{2a} are each a C_{1-6} alkyl or C_{3-8} cycloalkyl;

R is a -Cl, -Br, -I or -F;

5

R^1 is a H, Me, OMe, OCF₃, NHMe, NMe₂, -Cl, -Br, -I or -F;


R^2 is a H, -Cl, -Br, -I, -F or -O- C_1-C_6 alkyl;

10 R^3 is a H, -Cl, -Br, -I, -F, -O- C_1-C_6 alkyl, -NH- C_1-C_6 -acyl, -NO₂, -NHSO₂- C_1-C_4 -alkyl, -CN or -O-(CH₂)₁₋₄-COOH;

X is -O- or -S-;

15 R^4 and R^5 are each independently H, -Cl, -Br, -I, -F or -O- C_1-C_6 alkyl;


Q is a member selected from the group consisting of:



20 R^1 are each independently a H, -Cl, -Br, -I or -F.

3. A compound of claim 1, wherein:

A is a member selected from the group consisting of:



R is a -Cl, -Br, -I or -F;

5

R¹ is a H, -Cl, -Br, -I or -F;

R² is a H, -Cl, -Br, -I, -F or -O-C₁₋₆alkyl;

10 R³ is a H, -Cl, -Br, -I, -F, -O-C₁₋₆alkyl, -NH-C₁₋₆acyl, -NO₂, -NHSO₂-C₁₋₄alkyl, -CN and -O-(CH₂)₁₋₄-COOH;


R⁴ is a H, -Cl, -Br, -I, -F, -O-C₁₋₆alkyl, -NH-C₁₋₆acyl, -NO₂, -NHSO₂-C₁₋₄alkyl, -CN and -O-(CH₂)₁₋₄-COOH;

15

X is -O- or -S-;


R⁶ and R⁷ are each independently a H, -Cl, -Br, -I, -F or -O-C₁₋₆alkyl;

20 Q is a member selected from the group consisting of:



R^1 is a H, -Cl, -Br, -I or -F.


5 4. A compound of claim 1 of formula (I) having one of the following structures:



wherein:

10 A is a member selected from the group consisting of:

56



R¹ is a H, -F, -Cl, -OMe, -Me, -OCF₃, -SO₂Me, -NMe₂, or -SMe;

5 R² is a H, -Cl, F, Br, -OMe or -NMe₂;


R^3 is a H, -Cl, F, Br, -OMe or -NMe₂;

R^4 is a H, -Cl, F, Br, -OMe or -NMe₂ and


10

R is a -F, -Cl, or -Br.

5. A compound selected from the group consisting of:



15



and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

6. A pharmaceutical composition for preventing or treating a condition in a
5 mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of one of claims 1-5.
7. A method for preventing or treating a condition in a mammal characterized
10 by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of one of claims 1-5.
8. The method of claim 7, wherein the condition is selected from the group consisting of:
15 acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular
20 coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, and
25 conditions requiring the fitting of prosthetic devices.
9. A method for inhibiting the coagulation of biological samples comprising the administration of a compound of one of claims 1-5.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number
WO 02/026718 A3

- (51) International Patent Classification⁷: **C07D 239/91**, 401/04, 409/14, 401/14, 487/04, A61K 31/517, 31/519, A61P 7/02, C07D 409/04, 495/04
- (74) Agent: **LEE, Christine, S.**; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, NW, Washington, DC 20004 (US).
- (21) International Application Number: PCT/US01/30335
- (22) International Filing Date: 1 October 2001 (01.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/236,331 29 September 2000 (29.09.2000) US
- (71) Applicant (for all designated States except US): **MILLENNIUM PHARMACEUTICAL, INC.** [US/US]; 256 East Grand Avenue, South San Francisco, CA 94080 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ZHANG, Penglie** [CN/US]; 251 Winchester Court, Foster City, CA 94404 (US). **LI, Wenhao** [CN/US]; P.O. Box 1993, South San Francisco, CA 94083 (US). **HUANG, Wenrong** [CN/US]; 7723 Huntridge Lane, Cupertino, CA 95014 (US). **WANG, Lingyan** [CN/US]; 25 Hickory Place # H-21, Chatham, NJ 07928 (US). **JIA, Zhaozhong, Jon** [CN/US]; 1576-E Marina Court, San Mateo, CA 94404 (US). **SCARBOROUGH, Robert, M.** [US/US]; 22 Greenbrier Court, Half Moon Bay, CA 94019 (US). **ZHU, Bing-Yan** [CA/US]; 135 Lois Lane, Palo Alto, CA 94303 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
29 August 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BICYCLIC PYRIMIDIN-4-ONE BASED INHIBITORS OF FACTOR XA



(57) Abstract: Novel bicyclic pyrimidin-4-one-containing compounds of formulae (I) or (II): including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful *in vitro* or *in vivo* for preventing or treating conditions in mammals characterized by undesired thrombosis.

WO 02/026718 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/30335

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/91 C07D401/04 C07D409/14 C07D401/14 C07D487/04
 A61K31/517 A61K31/519 A61P7/02 C07D409/04 C07D495/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 276 295 A (MASAYUKI ISHIKAWA) 30 June 1981 (1981-06-30) column 1 -column 2; claims; table 1	1,6
A	WO 99 54313 A (BOEHRINGER) 28 October 1999 (1999-10-28) page 58 -page 63; claims	1,6,9

☐ Further documents are listed in the continuation of box C.


Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
 E earlier document but published on or after the international filing date
 L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 O document referring to an oral disclosure, use, exhibition or other means
 P document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 & document member of the same patent family

Date of the actual completion of the international search

16 May 2002

Date of mailing of the international search report

29/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/30335

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4276295	A	30-06-1981	JP 56051461 A	09-05-1981
			JP 56057768 A	20-05-1981
			JP 56065877 A	03-06-1981
			JP 55083761 A	24-06-1980
			AR 225028 A1	15-02-1982
			AU 526309 B2	06-01-1983
			AU 5393279 A	26-06-1980
			CA 1111849 A1	03-11-1981
			CH 644112 A5	13-07-1984
			DD 150462 A5	02-09-1981
			DE 2950376 A1	10-07-1980
			DK 539979 A	20-06-1980
			ES 487014 D0	16-12-1980
			ES 8102102 A1	01-04-1981
			ES 493758 D0	16-11-1981
			ES 8202333 A1	16-04-1982
			FR 2444671 A1	18-07-1980
			GB 2040927 A , B	03-09-1980
			HU 182733 B	28-03-1984
			IT 1126577 B	21-05-1986
			NL 7909118 A	23-06-1980
			NO 794135 A	20-06-1980
			NZ 192392 A	15-02-1983
			SE 7910376 A	20-06-1980
			YU 306379 A1	31-12-1983
			AT 375651 B	27-08-1984
			AT 801179 A	15-01-1984
			BE 880720 A1	19-06-1980
			ZA 7906892 A	31-12-1980
WO 9954313	A	28-10-1999	DE 19816983 A1	21-10-1999
			AU 4030399 A	08-11-1999
			CA 2323606 A1	28-10-1999
			WO 9954313 A1	28-10-1999
			EP 1071669 A1	31-01-2001
			US 6200976 B1	13-03-2001